NEWTON, Mass.--(BUSINESS WIRE)--Inflammasome Therapeutics, a private company, has completed enrollment of a Phase I PK/Safety study of its new brain- and retina-penetrant drug K9, which has application in the treatment of multiple neuroinflammatory, degenerative diseases (such as Alzheimer’s, MS, ALS, Parkinson’s, geographic atrophy) and autoimmune diseases such as lupus and thyroid eye disease..

马萨诸塞州牛顿市。-（商业新闻短讯）--一家私营公司Inflammasome Therapeutics已完成其新型脑和视网膜渗透药物K9的I期PK/安全性研究的注册，该药物可用于治疗多种神经炎症，退行性疾病（如阿尔茨海默氏病，MS，ALS，帕金森氏病，地理萎缩）和自身免疫性疾病，如狼疮和甲状腺眼病。。

“These diseases all involve a type of inflammation called inflammasome activation, and the activation of two specific inflammasomes catalyzes the progression of these diseases. K9, taken as a tablet, penetrates the brain and retina and blocks both inflammasomes,” said Dr. Paul Ashton, CEO and cofounder of Inflammasome Therapeutics.

“这些疾病都涉及一种称为炎性体激活的炎症，两种特定炎性体的激活会催化这些疾病的进展。K9作为一种片剂，可以穿透大脑和视网膜，阻断两种炎性体，”炎性体治疗学首席执行官兼联合创始人保罗·阿什顿博士说。

“Drugs that block a single inflammasome have been found to have only moderate or no efficacy in models of MS and macular degeneration; we have seen dramatically superior results with our Kamuvudine molecules that block multiple inflammasomes.”.

“已发现阻断单个炎性体的药物在MS和黄斑变性模型中仅具有中等或无疗效；我们已经看到阻断多种炎性体的卡莫夫定分子具有显着优越的效果。”。

Delivering therapies across the tightly controlled blood-brain and blood-retina barriers to reach disease targets that are responsible for driving smoldering neuroinflammation within the central nervous system has been a formidable challenge in advancing innovation in neurological and retinal diseases.

在严格控制的血脑和血视网膜屏障上提供治疗，以达到负责驱动中枢神经系统内阴燃性神经炎症的疾病目标，这是推进神经和视网膜疾病创新的一项艰巨挑战。

“Our data reveal that Kamuvudines have disease-modifying potential by targeting inflammation directly in the central nervous system as well as in the periphery,” said Dr. Jayakrishna Ambati, Inflammasome Therapeutics’ co-founder..

“我们的数据显示，卡姆夫定通过直接针对中枢神经系统和周围的炎症而具有改善疾病的潜力，”炎性体治疗联合创始人Jayakrishna Ambati博士说。。

The successful completion of this study paves the way for further clinical trials of the drug, which Inflammasome Therapeutics expects to commence later this year.

这项研究的成功完成为该药物的进一步临床试验铺平了道路，炎性体疗法预计将于今年晚些时候开始。

The company’s other dual inflammasome inhibitor entered clinical trials earlier this year for geographic atrophy, a late stage of macular degeneration that is one of the most common causes of blindness in the elderly without a meaningfully effective treatment. That drug, K8, is delivered via a sustained delivery implant that is injected directly into the eye and releases minute but effective amounts of drug for three months..

该公司的另一种双重炎性体抑制剂今年早些时候进入了临床试验，用于治疗地理萎缩，这是黄斑变性的晚期，是老年人失明的最常见原因之一，没有有效的治疗方法。这种药物K8是通过持续递送植入物递送的，该植入物直接注射到眼睛中，并在三个月内释放出微小但有效的药物量。。

Dr. Ambati has spent more than a decade leading research into the role of inflammasomes in triggering the inflammation that is believed to be the underlying cause of several neurodegenerative, autoimmune, and ophthalmic conditions for which there are no cures. Earlier, his research found that people taking a type of anti-HIV drug (called NRTIs) have a far lower risk of developing Alzheimer’s disease and geographic atrophy.

。早些时候，他的研究发现，服用一种抗艾滋病毒药物（称为NRTIs）的人患阿尔茨海默病和地理萎缩的风险要低得多。

Unfortunately, NRTIs also have substantial toxicity. This led Dr. Ambati and his team to create new molecules formed by altering the structure of NRTIs to remove their toxicity creating a new class of drugs, Kamuvudines. Kamuvudines, have the same inflammasome-inhibiting action as their predecessors, but none of the toxicity..

不幸的是，NRTI也有很大的毒性。这导致Ambati博士和他的团队通过改变NRTIs的结构来产生新的分子，以消除其毒性，从而产生了一类新的药物，卡莫夫定。卡穆夫定与前几类药物具有相同的炎性体抑制作用，但没有毒性。。

Inflammasome Therapeutics (https://www.inflam.com) was founded by Jayakrishna Ambati, M.D. and Paul Ashton, Ph.D. to advance therapies for prevalent, degenerative diseases and to advance novel delivery technologies for sustained release of therapeutic agents and compounds. The company combines scientific excellence with proven development expertise and works to create breakthrough products via a mixture of licensing agreements and internal development..

炎性体疗法(https://www.inflam.com)由医学博士Jayakrishna Ambati和博士Paul Ashton创立，旨在推进流行性退行性疾病的治疗，并推进用于持续释放治疗剂和化合物的新型递送技术。该公司将卓越的科学知识与成熟的开发专业知识相结合，通过许可协议和内部开发相结合，努力创造突破性的产品。。